{"name":"Reponex Pharmaceuticals A/S","slug":"reponex-pharmaceuticals-a-s","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPOWVTVXFXd1VmV1V6c0VJVmhUNnFabnNzT1J0YWNQZDBoSFMwSTFCTjQxY2NOVm10WnEwalY3VUNUNUY4Q3dLYkJIVDlNWjJpSE50R08yYk16TWtvYjJwVl9CWU13ZUdzQWJHWjlpMWdQRHh2Qm14c2dub28xamk2WG4xRl8tX3VDdDVvV3g3QW84NHRjN091T21tRQ?oc=5","date":"2026-03-25","type":"pipeline","source":"marketscreener.com","summary":"Pharma Equity Group A/S - Annual Report 2025 - marketscreener.com","headline":"Pharma Equity Group A/S - Annual Report 2025","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-25","type":"pipeline","source":"The Manila Times","summary":"Notice convening the annual general meeting in Pharma Equity Group A/S - The Manila Times","headline":"Notice convening the annual general meeting in Pharma Equity Group A/S","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-18","type":"pipeline","source":"The Manila Times","summary":"UPDATE OF THE FINANCIAL CALENDAR FOR 2026 - The Manila Times","headline":"UPDATE OF THE FINANCIAL CALENDAR FOR 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxNamI2akN3ZjVUdURMMFJwSkZZeTJWTm9RYzVjQ1Y5bEpIR0hEMEQybkpkbmhDZFllbXJVRDMtSHRHeENvbGpmNFFKclVESDRxam5hR2wxMXV6U1dkNHJ5N1BHTFU2WGtLVUFxTXh4NF83cTVKdXRlek8yVl9QWVpVcnFrQ0JGeDhldWZsQUlwX21jNTVMZ0toelVjM0FOOThLU3lrSXF2LWFaLXhvbXE5YTZUaTFBS1U2NFM4aXp3Z2NzSXRlNXVmaVlEd1RkUjlFM2c?oc=5","date":"2025-09-01","type":"regulatory","source":"Analyst Group","summary":"Comment on Pharma Equity Group’s regulatory approval to initiate Phase II clinical trial for RNX-011 - Analyst Group","headline":"Comment on Pharma Equity Group’s regulatory approval to initiate Phase II clinical trial for RNX-011","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxPUzY5M1dBMWlVMlc0SDNlSlBiUzhLcE0xX2lCcnhid21LSlRVTFpJT2dzMFdrQ3lldkRlYTFCYmlaZTZ5NFVEcVNJb1JaSGpYQmFVbDF4ZnRpWEpqaUIyQ21MalpzRkVEY1N0MUR3eENLeEpndXdkcWxrd3lOZ05WNGZjVWgzOW9mUmJmTUtiQWdTYV9aTmVZam9Pc0g5ZGVpRVVxNTQ4dlZET0drR1E5Z0ljMFRVdUhMRm9iNXVMdkdmeXFQQ3RNOTdmT0paNTRPSWVxTWZ2MUFNVmdtWXlCN3JVWnBlWTlyN29ZUzI3WkN5Z2pJV1FEYlNCYVk3WDhKRGQxeW8xdXJoNzlHQW9xQkxVMTE5bl9TRDloRXBkampOaEVPQTBYeU9URVd0RHdDc3ZOQWlTbFZPX0YxZWpueDNUc0JKSVk?oc=5","date":"2024-10-23","type":"pipeline","source":"globenewswire.com","summary":"Pharma Equity Group's subsidiary (Reponex Pharmaceuticals - globenewswire.com","headline":"Pharma Equity Group's subsidiary (Reponex Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNSjVUTC1Ed0dveWgwMW55bWUtNW9xRWZad1hzcmpaalRUV29YWlVyUHRnZ3QwVkNwLWQwWXNyd2hlZ2NESUdiQl9SNWNtd2NQVXhicFk0VklBUlhvZnItejBVU0VjS0FpcHZ6N0EzY205QS0tTFBVSUpka0VPQ3ljZmNDaWZxWHZxWnhaM21ZWTN0VEhQbXFMN0FXZ0ZVWnRYMGlpeVlPVDZ6ZW8?oc=5","date":"2024-04-05","type":"trial","source":"OncLive","summary":"Phase 2 Data Support Use of RNX-051 in Cancerous and Precancerous CRC - OncLive","headline":"Phase 2 Data Support Use of RNX-051 in Cancerous and Precancerous CRC","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-10-31","type":"patent","source":"NTB Kommunikasjon","summary":"Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) receives a notification from the EPO regarding the “Intention to Grant” for patents of the subsidiary's wound-healing drug combination an","headline":"Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) receives a notification from the EPO regarding the “Inten","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}